Literature DB >> 9824486

Vitamin D differentially regulates B7.1 and B7.2 expression on human peripheral blood monocytes.

A Clavreul1, C L D'hellencourt, C Montero-Menei, G Potron, D Couez.   

Abstract

The hormonal active form of vitamin D3, 1,25-dihydroxyvitamin D3 (1, 25(OH)2D3), inhibits (through an unknown mechanism) the ability of monocytes/macrophages to induce T-cell activation. For T cells to be optimally activated, recognition of antigen/major histocompatibility complexes (MHC) by the T-cell receptor (TCR) must be accompanied by a second costimulatory signal. Considerable experimental data now suggest that this costimulatory signal is predominantly generated by B7.1 and/or B7.2 molecules, expressed on antigen-presenting cells (APC), when engaged to their counter-receptor, CD28, present on T cells. To determine whether the inhibitory effect of 1,25(OH)2D3 on monocytes/macrophages might involve modulation of the expression of B7.1 and B7.2 molecules, we analysed (by flow cytometry) the influence of 1,25(OH)2D3 and an analogue, KH 1060, on the expression of these two molecules at the surface of resting human peripheral blood monocytes. In parallel, we tested the effect of these two agents on human monocyte expression of cell-surface markers (CD14 and CD4) and antigen-presenting molecules (MHC class I and MHC class II). Our results showed that both 1,25(OH)2D3 and KH 1060 inhibited the basal expression of B7.2 in a dose- and time-dependent manner, without affecting B7.1. Moreover, these two compounds increased CD14 and reduced MHC class II and CD4 expression. Furthermore, the effect of 1,25(OH)2D3 on B7 molecule expression in combination with lipopolysaccharide (LPS) or cytokines, including interleukin-10 (IL-10), interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha), was studied. The 1,25(OH)2D3-induced B7.2 down-regulation was still detectable when monocytes were activated by IL-10, IFN-gamma and TNF-alpha but not with LPS. Moreover, the induction of B7.1 by TNF-alpha was inhibited by addition of 1, 25(OH)2D3. We conclude that the ability of 1,25(OH)2D3 to decrease B7.2 expression on human monocytes might contribute to its inhibitory effect on APC-dependent T-cell activation and to its immunosuppressive properties observed in autoimmune diseases and organ transplantation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9824486      PMCID: PMC1364315          DOI: 10.1046/j.1365-2567.1998.00588.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  35 in total

Review 1.  Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation?

Authors:  C B Thompson
Journal:  Cell       Date:  1995-06-30       Impact factor: 41.582

Review 2.  Immunomodulatory effects of 1,25-dihydroxyvitamin D3.

Authors:  K Casteels; R Bouillon; M Waer; C Mathieu
Journal:  Curr Opin Nephrol Hypertens       Date:  1995-07       Impact factor: 2.894

3.  Transplantation tolerance induced by CTLA4-Ig.

Authors:  T C Pearson; D Z Alexander; K J Winn; P S Linsley; R P Lowry; C P Larsen
Journal:  Transplantation       Date:  1994-06-27       Impact factor: 4.939

4.  1,25 Dihydroxyvitamin D3 exerts regional effects in the central nervous system during experimental allergic encephalomyelitis.

Authors:  S Nataf; E Garcion; F Darcy; D Chabannes; J Y Muller; P Brachet
Journal:  J Neuropathol Exp Neurol       Date:  1996-08       Impact factor: 3.685

5.  Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype.

Authors:  W D Creery; F Diaz-Mitoma; L Filion; A Kumar
Journal:  Eur J Immunol       Date:  1996-06       Impact factor: 5.532

6.  Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes.

Authors:  F Willems; A Marchant; J P Delville; C Gérard; A Delvaux; T Velu; M de Boer; M Goldman
Journal:  Eur J Immunol       Date:  1994-04       Impact factor: 5.532

Review 7.  Immunomodulatory actions of 1,25-dihydroxyvitamin D3.

Authors:  J M Lemire
Journal:  J Steroid Biochem Mol Biol       Date:  1995-06       Impact factor: 4.292

8.  Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D3, KH1060.

Authors:  C Mathieu; M Waer; K Casteels; J Laureys; R Bouillon
Journal:  Endocrinology       Date:  1995-03       Impact factor: 4.736

9.  Treatment of murine lupus with CTLA4Ig.

Authors:  B K Finck; P S Linsley; D Wofsy
Journal:  Science       Date:  1994-08-26       Impact factor: 47.728

Review 10.  The B7 and CD28 receptor families.

Authors:  C H June; J A Bluestone; L M Nadler; C B Thompson
Journal:  Immunol Today       Date:  1994-07
View more
  3 in total

1.  Vitamin D regulation of OX40 ligand in immune responses to Aspergillus fumigatus.

Authors:  Nikki Lynn Hue Nguyen; Kong Chen; Jeremy McAleer; Jay K Kolls
Journal:  Infect Immun       Date:  2013-02-25       Impact factor: 3.441

2.  Effect of different 1, 25-(OH)2D3 doses on high mobility group box1 and toll-like receptors 4 expression in lung tissue of asthmatic mice.

Authors:  Junying Qiao; Bin Luan; Huiru Gu; Yanli Zhang
Journal:  Int J Clin Exp Med       Date:  2015-03-15

3.  Association of primary biliary cirrhosis with vitamin D receptor BsmI genotype polymorphism in a Hungarian population.

Authors:  B Halmos; F Szalay; T Cserniczky; E Nemesanszky; P Lakatos; S Barlage; G Schmitz; L Romics; A Csaszar
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.